Ihc - CD2 Hyderabad | Focus Diagnostics

IHC – CD2 Test

The IHC CD2 Test is a specialized immunohistochemistry (IHC) diagnostic test used to detect CD2 protein expression in tissue samples. CD2 is a surface glycoprotein commonly expressed on T-lymphocytes and natural killer (NK) cells, making it an important biomarker in the diagnosis and classification of T-cell and NK-cell lymphomas and leukemias.

This test plays a critical role in hematopathology, helping pathologists identify lymphoid cell lineage and distinguish T-cell neoplasms from B-cell lymphomas and other hematologic malignancies.

The IHC CD2 test is commonly used in evaluating:

• Peripheral T-cell lymphoma
• T-lymphoblastic lymphoma/leukemia
• NK/T-cell lymphoma
• Cutaneous T-cell lymphoma
• Differential diagnosis of lymphoid neoplasms

The test is performed on FFPE (Formalin-Fixed Paraffin-Embedded) tissue biopsy samples using advanced antibody staining techniques. Expert pathologists examine stained tissue microscopically to assess CD2 expression and determine the tumor’s cellular origin.

This test is often used as part of a broader lymphoma immunophenotyping panel alongside markers such as CD3, CD5, CD7, CD20, and others to ensure precise classification.

Accurate identification of CD2 positivity helps oncologists confirm diagnosis, assess prognosis, and guide personalized treatment planning for hematologic cancers.

Benefits of the Test

• Detects CD2 protein expression accurately
• Supports T-cell and NK-cell tumor diagnosis
• Helps classify lymphoma subtype
• Assists differential diagnosis
• Improves pathology diagnostic precision
• Supports personalized treatment planning

Why Doctors Recommend This Test

Doctors commonly recommend the CD2 IHC Test when:

• T-cell lymphoma is suspected
• NK-cell malignancy evaluation is required
• Lymphoid lineage clarification is needed
• Routine biopsy findings are inconclusive
• Advanced lymphoma classification is necessary
• Hematologic cancer subtype confirmation is required
• Treatment planning depends on exact diagnosis
• Expert hematopathology confirmation is needed

This test improves diagnostic confidence for accurate hematologic cancer management.

Preparation Before the Test

Preparation usually includes:

• Submission of FFPE tissue block or unstained slides
• Previous pathology reports
• Relevant imaging and clinical records
• Proper tissue labeling and packaging
• Laboratory authorization documentation

No fasting or direct patient preparation is required.

Normal Reporting Time

The normal reporting time for the CD2 IHC Test is usually 4–7 working days, depending on staining complexity and interpretation requirements.

Who Should Take This Test?

This test is recommended for:

• Patients with suspected T-cell lymphoma
• Individuals undergoing NK-cell tumor evaluation
• Patients requiring lymphoma subtype classification
• Individuals with unclear tissue diagnosis
• Hematology-oncology patients under specialist care
• Patients requiring advanced immunohistochemistry confirmation

At Focus Diagnostics Hyderabad, advanced immunohistochemistry technology and expert hematopathology specialists ensure highly accurate CD2 IHC reports for reliable diagnosis and personalized cancer treatment planning.